Renascience Provides Insights on PAI-1’s Role in Obesity and Studies on RS Drugs

TOKYO, Jul 16 (Pulse News Wire) – Renascience Inc. (4889.T) disclosed insights on the relationship between obesity and plasminogen activator inhibitor-1 (PAI-1).

Research shows that PAI-1 levels are significantly higher in obese individuals compared to non-obese ones, correlating with BMI (Diabetologia 41: 65-71). Recent studies indicate that PAI-1 inhibitors, such as RS drugs, reduce plasma PAI-1 activity and inhibit weight gain in mice fed high-fat diets (Frontiers in Pharmacology 2020, 11: Article 943). In collaboration with Tohoku University and international universities, Renascience conducted studies showing that PAI-1 inhibitors effectively reduced weight gain and white fat tissue mass in mice fed high-fat diets.

Specifically, treatment with RS drug led to a significant decrease in weight from 37.6 ± 1.07 grams in control groups to 33.8 ± 0.97 grams in treated groups. Additionally, the drug mitigated leptin resistance induced by high-fat diets, suggesting a mechanism for reducing appetite. Further research suggests that PAI-1 inhibitors could also promote weight loss and enhance fat breakdown in mice transitioning from high-fat to low-fat diets (Obesity 2021, 29: 713-724).

While these findings are based on mouse models, they hint at potential applications in human health, particularly in combating obesity-related conditions and aging-associated diseases.